Key Highlights

  • AstraZeneca (NYSE:AZN) reported third quarter Revenue of USD 16.209 billion, up 7 percent, with core EPS of USD 2.79, up 17 percent, and reaffirmed full-year guidance for mid-to-high single digit revenue growth.
  • Sanofi (NASDAQ:SNY) reported third quarter sales of 14.444 billion euro, up 14.3 percent at constant exchange rates, with Dupixent sales of 5.7 billion euro, up 34.8 percent, and Business EPS of 3.55 euro.
  • Sanofi raised 2026 guidance to low-teens sales growth and mid-teens business EPS growth at constant rates, while AstraZeneca left guidance unchanged but announced a USD 1.5 billion savings program, as reported.
  • Premarket gains on October 30 were about 4.5 percent for AstraZeneca and 3.9 percent for Sanofi; London shares of AstraZeneca rose about 7 percent intraday to GBP 139.66.

AstraZeneca Holds Course

AstraZeneca published nine month revenue of USD 46.881 billion, up 7 percent, and core EPS of USD 8.00, up 14 percent. Its ordinary shares moved from Nasdaq to a direct listing on the New York Stock Exchange in February 2026, so the correct tag is AstraZeneca (NYSE:AZN), not a Nasdaq listing. Management cited more than USD 20 billion of potential from 2027 clinical trial readouts and a positive survival result for a Tagrisso combination in lung cancer. Generic competition to Farxiga remains a headwind, and the savings program, reported at USD 1.5 billion, is intended to fund pipeline spending. Third quarter core EPS rose faster than revenue, which points to Operating Leverage rather than price alone.

Sanofi Upgrades Guidance

Sanofi reported on October 30, 2026. Net sales rose 16.2 percent on a reported basis and 14.3 percent at constant exchange rates, while IFRS EPS was 2.52 euro and business EPS rose 22.0 percent at actual rates. Dupixent, its immunology medicine, is the engine: 5.7 billion euro of sales is roughly 39.5 percent of the quarter, straightforward arithmetic on two published figures. Sanofi (NASDAQ:SNY) lifted guidance to low-teens sales growth and mid-teens business EPS growth at constant rates, a more explicit signal than AstraZeneca's reaffirmation. Management also reiterated its commitment to a progressive dividend, though it did not announce a new buyback in the release reviewed.

Risks and Peer Context

Concentration is the main risk at Sanofi (NASDAQ:SNY) because one medicine drives so much growth, and any competitive or pricing change in immunology would show up quickly. At AstraZeneca, generic erosion, trial outcomes and United States pricing policy matter more than any single quarter. US-listed shares also move with currency and the broader market, and the Nasdaq Composite fell nearly 3 percent that day, which makes the defensive pharma gains notable. Closing moves for the US lines were not available at the time of writing, so readers should confirm them on a live quote. Neither result alters the longer-term Patent timelines that investors track closely.

Where Things Stand

The two drugmakers were AstraZeneca and Sanofi, which rose on October 30 as strong quarterly numbers met a risk-off tape. AstraZeneca (NYSE:AZN) grew revenue 7 percent and held guidance, while Sanofi accelerated and raised guidance on a 34.8 percent Dupixent surge. Pharma offers defensive earnings, yet concentration, patent expiry and drug pricing remain live risks. Upcoming catalysts are 2027 trial readouts at AstraZeneca and Dupixent trends at Sanofi.